US2019218511A1PendingUtilityA1
Methods and compositions for targeting progenitor cell lines
Est. expiryAug 22, 2032(~6.1 yrs left)· nominal 20-yr term from priority
C07K 7/08C12N 5/0606
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.
Claims
exact text as granted — not AI-modified1 . A method of enriching a population of progenitor cells, wherein the progenitor cell is the in vitro progeny of pluripotent stem cell, comprising contacting a population of cells comprising the progenitor cell with a peptide that binds specifically to the progenitor cell and separating the progenitor cell bound to the peptide from the population of cells thereby enriching for a population of progenitor cells.
2 . The method of claim 1 , wherein the peptide is chosen from
SWTYSYPNQNMD;
(SEQ ID NO: 1)
DWTYSLPGLVEE;
(SEQ ID NO: 2)
NWTWSMPTGNPA;
(SEQ ID NO: 3)
GMTLRVLTN-YTE-;
(SEQ ID NO: 4)
TLHVSENSWTYN;
(SEQ ID NO: 5)
DWLWSFAPNVDT;
(SEQ ID NO: 6)
TLSSQNPYMHKK;
(SEQ ID NO: 7)
IDKQMMTSHKAI;
(SEQ ID NO: 8)
QGMETQKLRMLK;
(SEQ ID NO: 9)
GWYWETPLDMFN;
(SEQ ID NO: 10)
GWVIDYDYYPMR;
(SEQ ID NO: 11)
VTAENYQSFSVS;
(SEQ ID NO: 12)
NNKMDDRMMMSIV;
(SEQ ID NO: 13)
STGTDLHSNARI;
(SEQ ID NO: 14)
YEFDNLLNRTLW;
(SEQ ID NO: 15)
EWTVNERTMWDL.
(SEQ ID NO: 16)
3 . The method of claim 1 , wherein the progenitor cell is a human cell.
4 . The method of claim 3 wherein the progenitor cell is an endoderm cell.
5 . The method of claim 3 , wherein the progenitor cell is a mesoderm cell.
6 . The method of claim 3 , wherein the progenitor cell is a W10 progenitor cell.
7 . The method of claim 3 , wherein the progenitor cell expresses the markers and neural crest derivatives-expressed 2 (HAND2), HOXA4 and HOXB7.
8 . The method of claim 1 , wherein the peptide has plexin homology.
9 . A peptide that binds to a progenitor cell chosen from
SWTYSYPNQNMD;
(SEQ ID NO: 1)
DWTYSLPGLVEE;
(SEQ ID NO: 2)
NWTWSMPTGNPA;
(SEQ ID NO: 3)
GMTLRVLTN-YTE-;
(SEQ ID NO: 4)
TLHVSENSWTYN;
(SEQ ID NO: 5)
DWLWSFAPNVDT;
(SEQ ID NO: 6)
TLSSQNPYMHKK;
(SEQ ID NO: 7)
IDKQMMTSHKAI;
(SEQ ID NO: 8)
QGMETQKLRMLK;
(SEQ ID NO: 9)
GWYWETPLDMFN;
(SEQ ID NO: 10)
GWVIDYDYYPMR;
(SEQ ID NO: 11)
VTAENYQSFSVS;
(SEQ ID NO: 12)
NNKMDDRMMMSIV;
(SEQ ID NO: 13)
STGTDLHSNARI;
(SEQ ID NO: 14)
YEFDNLLNRTLW;
(SEQ ID NO: 15)
EWTVNERTMWDL.
(SEQ ID NO: 16)
10 . The peptide of claim 9 , wherein the peptide has plexin homology.
11 . A composition comprising a progenitor cell and a peptide specifically bound to the progenitor cell, wherein the progenitor cell is the in vitro progeny of a pluripotent stem cell.
12 . The composition of claim 11 , wherein the progenitor cell is a human progenitor cell.
13 . The composition of claim 12 , wherein the progenitor cell is an endoderm progenitor cell.
14 . The composition of claim 12 , wherein the progenitor cell is a mesoderm progenitor cell.
15 . The composition of claim 11 , wherein the progenitor cell is the W10 progenitor cell.
16 . The composition of claim 11 , wherein the progenitor cell expresses the markers neural crest derivatives-expressed 2 (HAND2), HOXA4 and HOXB7.
17 . The composition of claim 11 , wherein the peptide is chosen from
SWTYSYPNQNMD;
(SEQ ID NO: 1)
DWTYSLPGLVEE;
(SEQ ID NO: 2)
NWTWSMPTGNPA;
(SEQ ID NO: 3)
GMTLRVLTN-YTE-;
(SEQ ID NO: 4)
TLHVSENSWTYN;
(SEQ ID NO: 5)
DWLWSFAPNVDT;
(SEQ ID NO: 6)
TLSSQNPYMHKK;
(SEQ ID NO: 7)
IDKQMMTSHKAI;
(SEQ ID NO: 8)
QGMETQKLRMLK;
(SEQ ID NO: 9)
GWYWETPLDMFN;
(SEQ ID NO: 10)
GWVIDYDYYPMR;
(SEQ ID NO: 11)
VTAENYQSFSVS;
(SEQ ID NO: 12)
NNKMDDRMMMSIV;
(SEQ ID NO: 13)
STGTDLHSNARI;
(SEQ ID NO: 14)
YEFDNLLNRTLW;
(SEQ ID NO: 15)
EWTVNERTMWDL.
(SEQ ID NO: 16)
18 . The composition of claim 11 , wherein the peptide has plexin homology.Join the waitlist — get patent alerts
Track US2019218511A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.